At its meeting on 17 June 2024, the Transparency Council adopted opinion No. 92/2023 on the inclusion in the reimbursement of medicines containing the active substance prednisoneum in terms of indications for use or dosage, or route of administration different from those specified in the Summary of Product Characteristics of Medicinal Product, i.e. eosinophilic enteritis in children under 18 years of age.
Publication on the list of opinions on active substances for off-label indications >>